Hepatic Arterial Blood Flow Modulation in Patients With Hepatocellular Carcinoma: Influence of Intra-arterial Norepinephrine Assessed With CT Perfusion
Dr Rajan is investigating a new method to improve local treatment of liver cancer. There is
evidence that a drug, norepinephrine (NE), has the ability to shrink down normal liver blood
vessels, but leave tumour vessels wide open. In patients with primary liver cancer, NE will
be injected directly in the artery that nourishes the liver and the tumour. Real time blood
flow will be measured using an advanced CT scanner to demonstrate the NE effect on blood
vessels. If Dr Rajan's hypothesis is confirmed, this drug has great potential to benefit
patients during local delivery of chemotherapy in the liver artery, diverting it away from
normal liver and towards the tumour, resulting in less complications and improved tumour kill.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society